**Core tip:** Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, and our knowledge of this infection is still insufficient in many respects. We present 3 cases with low-grade fever during COVID-19 convalescence. These cases highlight the main clinical, radiographic, and laboratory characteristics of COVID-19 and help provide guidance for frontline medical staff in terms of clinical management and individualized decision-making during convalescence.

INTRODUCTION
============

Since the outbreak in December 2019, coronavirus disease 2019 (COVID-19) has spread worldwide\[[@B1]\]. The number of infected cases and the death toll have markedly increased\[[@B2]\]. Studies have confirmed that COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) *via* human to human transmission\[[@B3]\]. Although there have been reports on the epidemiological and clinical characteristics of COVID-19\[[@B1],[@B4]\], our knowledge on this infection is still insufficient in many respects, such as symptoms, trends, prognosis, *etc*. In particular, if disease fluctuations or recurrence develop during convalescence, which refers to recovered non-febrile patients without respiratory symptoms\[[@B5]\], a patient\'s treatment may fail and the patient may spread the virus to others. Thus, we report 3 clinical cases of low-grade fever (axillary temperature of 37-38°C) during COVID-19 convalescence, and highlight the main clinical, radiographic, and laboratory characteristics. We hope that this report will enhance the knowledge of COVID-19 and help increase the level of expertise in frontline medical staff with regard to clinical management and individualized decision-making during convalescence.

CASE PRESENTATION
=================

Chief complaints
----------------

Patient A was a 62-year-old female who had a fever, cough, and anorexia for 1 wk, Patient B was a 66-year-old female with a fever and cough for 2 d, and Patient C was a 55-year-old male with a fever, cough, and fatigue for 4 d.

History of present illness
--------------------------

**Patient A:** From disease onset on 1 February 2020, the patient had a fever with a maximum axillary temperature of 39.8°C, which was accompanied by a cough and anorexia (details shown in Table [1](#T1){ref-type="table"}). The patient was considered to have a common upper respiratory tract infection and was treated with antibiotics and ribavirin. Isolation and preventive measures were not taken. The patient\'s condition did not improve, and COVID-19 was confirmed on February 7 by positive SARS-CoV-2 oropharyngeal swab test at our local Center for Disease Control (CDC). She was transferred to an isolation ward, and antiviral treatment with arbidol was administered. Her temperature returned to normal on February 10, but new lesions on computed tomography (CT) were observed on February 13 (Figure [1](#F1){ref-type="fig"}). Antibiotics and arbidol were discontinued on February 18 and February 20, respectively, and no drugs were used since then. During convalescence, the patient\'s cough and anorexia were completely relieved, and two consecutive SARS-CoV-2 tests were negative with an interval of at least 24 h between tests. However, she developed low-grade fever for 3 d from February 23 to 25 without any other discomfort or comorbidities, and her CT lesions were resolved (Figure [1](#F1){ref-type="fig"}). Her temperature returned to normal without treatment.

###### 

Information of the 3 patients at different time points

  **Patient A**             **Patient B**   **Patient C**                                         
  ------------------------- --------------- --------------- ------- ------- ------ ------- ------ -------
  Age in yr                                                                                       
  62                        66              55                                                    
  Female                    Female          Male                                                  
  Fever                                                                                           
  Yes                       No              Yes             Yes     No      Yes    Yes     No     Yes
  Cough                                                                                           
  ++                        \+              No              ++      \+      No     ++      \+     No
  Expectoration                                                                                   
  No                        No              No              ++      \+      No     \+      \+     No
  Anorexia                                                                                        
  ++                        \+              No              No      No      No     \+      No     No
  Fatigue                                                                                         
  \+                        \+              No              No      No      No     ++      \+     No
  Pharyngalgia                                                                                    
  No                        No              No              Yes     No      No     Yes     No     No
  Dyspnea                                                                                         
  No                        No              No              No      No      No     No      No     No
  Diarrhea                                                                                        
  No                        No              No              ++      \+      No     No      No     No
  Constipation                                                                                    
  No                        No              No              No      No      No     \+      No     No
  Insomnia                                                                                        
  \+                        \+              No              No      No      No     \+      No     No
  WBC: 4-10 × 10^9^/L                                                                             
  3.5                       4.8             3.8             2.9     4.0     3.5    3.3     5.8    3.2
  RBC: 3.5-5.5 × 10^12^/L                                                                         
  3.2                       3.1             2.5             3.6     3.4     3.1    4.6     3.2    3.8
  Hb: 110-160 g/L                                                                                 
  97.0                      89.0            73.0            112.0   105.0   96.0   145.0   99.0   115.0
  NEUT: 2-7 × 10^9^/L                                                                             
  1.7                       2.2             1.8             1.7     2.7     1.8    2.2     3.8    1.1
  LYM: 0.8-4 × 10^9^/L                                                                            
  1.6                       1.7             1.6             0.8     1.0     1.2    0.9     1.4    1.6
  PCT: 0.5-1.5 ng/mL                                                                              
  NA                        0.07            0.05            NA      0.11    0.05   NA      0.05   0.05
  CRP: ≤ 10 mg/L                                                                                  
  3.4                       0.9             0.8             7.2     1.6     0.8    68.7    0.8    0.8
  SAA: ≤ 10 mg/L                                                                                  
  NA                        10.3            9.0             NA      11.3    9.0    NA      8.2    9.1
  SARS-CoV-2 test                                                                                 
  P                         P               N               P       P       P      P       P      N

++: Severe; +: Mild or moderate. CRP: C-reactive protein; Hb: Hemoglobin; NA: Not available; N: Negative; NEUT: Neutrophils; P: Positive; PCT: Procalcitonin; PLT: Platelet; SAA: Serum amyloid A; RBC: Red blood cell; WBC: White blood cell.

![Computed tomography images of lesions in the 3 patients at different time points. New lesions appeared in patients A and C after temperature returned to normal. Lesions had resolved in all 3 patients when low-grade fever occurred. Red arrows indicate new lesions.](WJCC-8-2655-g001){#F1}

**Patient B:** From disease onset on 4 February 2020, the patient had a fever with a maximum axillary temperature of 38.1°C, accompanied by a cough (details shown in Table [1](#T1){ref-type="table"}) and multiple lesions on CT (Figure [1](#F1){ref-type="fig"}). The patient was considered to have a common upper respiratory tract infection and was treated with the Lianhua Qingwen tablet. Isolation and preventive measures were not taken. The patient\'s condition did not improve, and COVID-19 was confirmed on February 5 by positive SARS-CoV-2 oropharyngeal swab test at our local CDC. She was transferred to an isolation ward and was treated with lopinavir and ritonavir tablets. Her temperature returned to normal on February 8. Lopinavir and ritonavir tablets were discontinued on February 17, and no drugs were used since then. During convalescence, the patient\'s cough was completely relieved, and CT lesions resolved (Figure [1](#F1){ref-type="fig"}), but her SARS-CoV-2 test remained positive. She developed low-grade fever for 4 d from February 23 to 26 without other discomfort, comorbidities, or new CT lesions (Figure [1](#F1){ref-type="fig"}). Her temperature returned to normal without treatment.

**Patient C:** From disease onset on 31 January 2020, the patient had a fever with a maximum axillary temperature of 39.9°C, which was accompanied by a cough and fatigue (details shown in Table [1](#T1){ref-type="table"}). The patient was considered to have common upper respiratory tract infection and was treated with antibiotics. Isolation and preventive measures were not taken, and the patient\'s condition did not improve. COVID-19 was confirmed on February 3 by positive SARS-CoV-2 oropharyngeal swab test at our local CDC. He was transferred to an isolation ward and treated with arbidol, interferon, glucocorticoid, and expectorants. His temperature returned to normal on February 9, but multiple new CT lesions were observed on February 10 (Figure [1](#F1){ref-type="fig"}). All drugs were discontinued on February 13. During convalescence, the patient\'s cough and fatigue were completely relieved, and two consecutive SARS-CoV-2 tests were negative with an interval of at least 24 h between tests. However, he developed low-grade fever for 3 d from February 24 to 26 without any other discomfort or comorbidities, and his CT lesions resolved (Figure [1](#F1){ref-type="fig"}). His temperature returned to normal without treatment.

Personal and family history
---------------------------

Patient A had contact with a COVID-19-confirmed patient (not confirmed at that time). Patient B had no contact history in the affected regions or with infected persons. Patient C had contact with persons from Wuhan, China, where the epidemic was first identified.

Physical examination upon admission
-----------------------------------

In all 3 patients, Velcro rales were heard in both lungs at the onset and disappeared during convalescence.

Laboratory examinations
-----------------------

Blood cell analysis and SARS-CoV-2 test results in the 3 patients at different time points are shown in Table [1](#T1){ref-type="table"}. The results of blood biochemistry (hepatic function, renal function, electrolytes, lipid, and glucose), tumor biomarkers, and coagulation function were normal and are shown in [Supplementary Table 1](Supplementary Table 1).

Imaging examinations
--------------------

**Patient A:** On February 5 (onset stage), ground-glass opacities (GGO) were seen in the posterior right lower lung. On February 13 (temperature returned to normal), the lesion was significantly enlarged with solid shadows and blurred edges. On February 24 (low-grade fever stage during convalescence), the lesions had been absorbed and the density was decreased.

**Patient B:** On February 6 (onset stage), there were multiple irregular schistose GGO in both lungs (mainly under the pleura) with consolidations and strip shadows. On February 16 (temperature returned to normal) the lesions were partially absorbed, the range reduced, and the density decreased. On February 24 (low-grade fever stage during convalescence), the lesions were further absorbed and were less dense.

**Patient C:** On February 3 (onset stage), small patchy GGO appeared in the right lung. On February 10 (temperature returned to normal), the lesions were increased and enlarged, showing multiple irregular schistose GGO in both lungs (mainly under the pleura) and some strip shadows in the posterior left lower lung. On February 25 (low-grade fever stage during convalescence), the lesions were absorbed and reduced, with partial strip changes.

Images of lesions in all 3 patients at different time points are shown in Figure [1](#F1){ref-type="fig"}.

FINAL DIAGNOSIS
===============

The 3 patients were confirmed with COVID-19 by positive SARS-CoV-2 oropharyngeal swab test at our local CDC.

TREATMENT
=========

All 3 patients did not receive any treatment for low-grade fever, and body temperature returned to normal after several days.

OUTCOME AND FOLLOW-UP
=====================

The 3 patients had no recurrence of low-grade fever, any other discomfort, or comorbidities. Patients A and C had no recurrence of positive SARS-CoV-2 tests. SARS-CoV-2 tests in Patient B were negative on March 4 and did not change to positive.

DISCUSSION
==========

Self-limiting low-grade fever during COVID-19 convalescence is an atypical symptom of infectious diseases. The characteristics of the 3 presented cases are summarized as follows.

All 3 patients experienced leukopenia and neutropenia during low-grade fever. Leukopenia and neutropenia often indicate low immunity\[[@B6],[@B7]\] and are more common in COVID-19 patients than in non-COVID-19 patients\[[@B8]\]. The trend in white blood cells in the 3 patients shifted with disease onset, normothermia, and low-grade fever. That is, leukopenia occurred during the course of fever but returned to normal when the patients were normothermic. We speculate that these patients with COVID-19 had low-grade fever during convalescence because their immunity was not fully recovered at this stage. This suggests that disease fluctuations and recurrence of positive SARS-CoV-2 may occur in convalescence\[[@B9]\], thus surveillance cannot be relaxed at this stage.

The CT features in the 3 patients were consistent with typical COVID-19 and include involvement of both lung parenchyma and interstitium; the GGO and a single lesion appearing in early-phase of disease; coexistence of aggravation and repair of CT signs in the advanced phase; and presentation of multifocal distributions in the middle and lower lung areas and the posterior lung region\[[@B10]\]. Other studies have reported that during recovery from COVID-19 (without severe respiratory distress), severe lung abnormalities are seen approximately 10 d after initial onset of symptoms\[[@B11]\]. This suggests that changes in CT lesions are not directly related to body temperature, and these two sets of data could complement each other in risk assessment of COVID-19.

During the course of low-grade fever, the 3 patients had no other discomfort or comorbidities, and their temperature returned to normal without any treatment. We speculate that low-grade fever may be driven by SARS-CoV-2 evolution with genetic diversity. Phan\[[@B3]\] found mutations and deletions on coding and non-coding regions in complete or near-complete genomes of SARS-CoV-2. Therefore, the emergence of deficient genomes during mutation and recombination of the virus is not surprising\[[@B12]\], and this is similar to cell wall-deficient bacteria\[[@B13]\]. Non-dominant deficient genomes can easily escape immune attacks while dominant genomes are cleared. It is notable that this defective genome may benefit patients by interfering with complete viral replication\[[@B14]\] and stimulating the host\'s antiviral immune response\[[@B15]\].

It is noteworthy that two of the 3 patients had consecutive negative SARS-CoV-2 tests with an interval of at least 24 h between tests but another patient remained positive when low-grade fever occurred. To date, no research has accurately confirmed the contagious period of COVID-19. The return of a positive SARS-CoV-2 RNA test during convalescence has been reported\[[@B9]\]. In addition to the basic immunity of the host and the high-mutation biological characteristics of SARS-CoV-2, detection could be affected by the site at which specimens are obtained, operators' experience, and the actual viral load\[[@B9],[@B16]\]. Furthermore, SARS-CoV-2 infection mainly focuses on the lungs rather than the upper respiratory tract\[[@B17]\], and some studies have indicated that higher viral loads have been detected in the nose than in the throat\[[@B9]\]; thus, sampling during the recovery stage using throat a swab or sputum may not detect the virus.

Given the possibility of turning positive again for SARS-CoV-2 and to provide warnings for other COVID-19 cases, we suggest that: (1) Multiple biological sample tests should be considered, including oropharyngeal swabs, nasopharyngeal swabs, sputum, bronchoalveolar lavage fluid, blood, stool, and urine, especially for highly suspected false-negative SARS-CoV-2 candidates; (2) The number of consecutive negative SARS-CoV-2 tests with an interval of at least 24 h between tests should be increased to 3 before discharge; (3) All discharged patients should extend home quarantine for at least 21 d; and (4) Patients who have not turned negative for SARS-CoV-2 more than 1.5 mo should be closely monitored and even during convalescence should also be regularly tested for risk assessment.

CONCLUSION
==========

Low-grade fever during convalescence is an atypical symptom of COVID-19. These cases are not rare, but the mechanism and outcome of low-grade fever during convalescence is not yet completely clear. Enhancing the knowledge on low-grade fever during COVID-19 convalescence might facilitate refined risk surveillance, precision risk assessment, and dynamic risk management, thereby increasing the level of expertise for tailored delivery of optimal healthcare services for each patient with COVID-19.
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